PATH | VRL
Menu

The RTS,S/AS01 Malaria Vaccine in Children 5 to 17 Months of Age at First Vaccination

This article, published in Expert Review of Vaccines, reviews the findings around the safety and feasibility of the RTS,S/AS01 vaccine in children at 5 to 17 months of age—an age category for which RTS,S/AS01 pilot implementation was recommended by the World Health Organization (WHO). The trial was conducted in seven sub-Saharan African countries and found that a four-dose schedule of RTS,S/AS01 was efficacious within the study population, providing the greatest impact against clinical and severe malaria. Further modeling found a significant number of severe malaria cases and deaths could be prevented by the vaccine candidate, particularly in areas with moderate-to-high malaria transmission. The article also explores key considerations and expectations for RTS,S/AS01 implementation in the wake of WHO’s recommendation of pilot implementation of the vaccine candidate.

Author: Vandoolaeghe P, Schuerman L

Published: 2016

» Visit web page (English)

(Located at www.tandfonline.com)

Citation: Vandoolaeghe P, Schuerman L. The RTS,S/AS01 Malaria Vaccine in Children 5 to 17 Months of Age at First Vaccination. Expert Review of Vaccines. 2016;15(12):1481-1493. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Malaria

Topics: Disease burden and surveillance, Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa